dopamine receptor agonists (dopamine responsive conditions) Flashcards
uses of bromocriptine (3)
galactorrhoea
treatment of prolactinomas (when it reduces both plasma prolactin concentration and tumour size)
sometimes in acromegaly
bromocriptine inhibits release of GH so is sometimes used in treatment of acromegaly but the following are more effective
but somatostatin analogues (such as octreotide) are more effective.
patients intolerant of bromocriptine may be able to tolerate the following drug, even though it has similar SE
and vice versa
cabergoline
what is quinaglotide
non-ergot dopamine D2 agonist.
which non ergot D2 agonist has actions and uses similar to ergot derives DRA but its SE differ slightly
quinaglotide
is quinaglotide an ergot derives DRA
NO it is NON ergot derived
what is quinaglotide used for
Hyperprolactinaemia
In hyperprolactinaemic patients, the source of the hyperprolactinaemia should be established (i.e. exclude pituitary tumour before treatment).
these two drugs are licensed to suppress lactation but not recommended for routine suppression, or for the relief of symptoms of PP pain and engorrgement that can be adequately treated with simple analgesics and breast support
bromocriptine and cabergoline
Although bromocriptine and cabergoline are licensed to suppress lactation, they are not recommended for routine suppression (or for the relief of symptoms of postpartum pain and engorgement) that can be adequately treated with simple analgesics and breast support. If a dopamine-receptor agonist is required, which one is preferred
cabergoline
this drug is not licensed for suppression of lactation
quinaglotide
important safety info for bromocriptine, cabergoline, quinaglotide
Impulse control disorders
Treatment with dopamine-receptor agonists is associated with impulse control disorders, including pathological gambling, binge eating, and hypersexuality. Patients and their carers should be informed about the risk of impulse control disorders.
Sudden onset sleep
Hypotensive reactions
quinaglotide monitoring
BP a few days after starting treatment and following dose increase